Stereoselectivity of oxotremorine antagonists containing a chiral pyrrolidine group

Summary Oxotremorine (Ia) and its succinimide analogue (IIa) have been substituted in the pyrrolidine ring with a methyl group in the 2- or 3-positions. The compounds are oxotremorine antagonists. The 2-methyl-substituted enantiomers show stereoselectivity, the S-isomers being the most active.     

N-(t-Aminoalkynyl)-substituted pyrrolidones as oxotremorine antagonists

Zusammenfassung Eine Anzahl von Antagonisten zu Oxotremorin wurden durch kleine Modifikationen der Struktur des Oxotremorins erhalten. Die aktivste Verbindung, N-(1-Methyl-4-pyrrolidino-2-butinyl)pyrrolidon, ist mehr als sechsmal wirksamer als Atropin und hat eine grössere Spezifizität mit Bezug auf das Zentralnervensystem.     

Stereospecificity of allantoin degradation inStreptococcus allantoicus

Zusammenfassung Die Stereospezifität der Enzyme des Allantoinabbaus inStreptococcus allantoicus und die optische Drehung der Reaktionsprodukte wurde bestimmt. Allantoinase war aspezifisch, während Allantoate-amidohydrolase ausschliesslich (-)-Ureidoglykolate bildete. Diese Substanz wurde durch (-)-Ureidoglykolase hydrolysiert.     

Stereospecificity of hydrogen transfer of aldehyde reductase

Summary Aldehyde reductase from human liver catalyzes the hydrogen transfer from the pro-4R position on the dihydronicotinamide ring of the coenzyme to there face of the carbonyl carbon atom of the substrate.     

Pressor response to oxotremorine in atropinized rats

Zusammenfassung Eine zentrale, nikotinartige Wirkung von Oxotremorin wird am Blutdruck der Ratte beschreiben.     

Stereospecificity of hydrogen transfer of aldehyde reductase.

Aldehyde reductase from human liver catalyzes the hydrogen transfer from the pro-4R position on the dihydronicotinamide ring of the coenzyme to the re face of the carbonyl carbon atom of the substrate.     

Stereospecificity of the prostaglandin 15-dehydrogenase from swine lung

Zusammenfassung Die stereochemischen Voraussetzungen der Prostaglandin-15-Dehydrogenase aus Schweinelunge werden im Hinblick auf die pharmakologische Aktivität anhand einer Reihe synthetischer Prostaglandin E₁-Präparate abgeklärt.

---

---

This work was supported by grants from the U.S. National Institutes of Health to Harvard University and by O.N.R. and N.I.H. grants to the Worcester Foundation for Experimental Biology.     

Integrin antagonists

Integrins are a family of cell surface glycoproteins that mediate numerous cell-cell and cell-matrix interactions and are involved in biological processes such as tissue morphogenesis, leukocyte recirculation and migration, wound healing, blood clotting and immune response. Aberrant cell adhesion has been implicated in the pathogenesis of several diseases, including a number of inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease and asthma, as well as cancer and coronary heart disease. As such integrins are seen as excellent targets for the development of therapeutic agents. This report begins with an examination of the structure of integrin molecules and their ligands and then goes on to review the current state of development of antiintegrin antagonists. Received 13 April 1999; received after revision 28 May 1999; accepted 28 May 1999     

Vasopressin antagonists

Effects of vasopressin via V1a- and V2-receptors are closely implicated in a variety of water-retaining diseases and cardiovascular diseases, including heart failure, hyponatraemia, hypertension, renal diseases, syndrome of inappropriate antidiuretic hormone secretion, cirrhosis and ocular hypertension. As vasopressin receptors are found in many different tissues, vasopressin antagonists may benefit the treatment of disorders such as cerebral ischaemia and stroke, Raynaud’s disease, dysmenorrhoea and tocolytic treatment. V1b selective vasopressin antagonists are discussed in terms of their usefulness in the treatment of emotional and psychiatric disorders. The vaptans are vasopressin receptor antagonists with V1a (relcovaptan) or V2 (tolvaptan, lixivaptan) selectivity or non-selective activity (conivaptan) which may be advantageous in some disorders. The V1a/V2 non-selective vasopressin antagonist conivaptan is the first vaptan which is approved by the FDA for the treatment of euvolaemic hyponatraemia. Received 3 February 2006; received after revision 16 March 2006; accepted 26 April 2006     

Anticoccidial riboflavine antagonists

Summary 4 types of riboflavine antagonists have broad-spectrum activity in poultry coccidiosis. 5-Deazariboflavine is most effective. 10-Benzyl analogs of riboflavine control intestinal species of coccidia.     

Modulation of dopaminergic transmission by alpha-noradrenergic agonists and antagonists: Evidence for antidopaminergic properties of some alpha antagonists

Summary The effects on dopamine (DA) metabolism, on³H-spiperone binding and on amphetamine-induced stereotypies of a variety of drugs with different actions on alpha₁-and alpha₂-noradrenergic (NA) receptors have been investigated.The preferential alpha₂-antagonists yohimbine, rauwolscine, piperoxane and esproquin as well as the preferential alpha₁-antagonists corynanthine and WB4101 increased homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) in the rat striatum, mesolimbic area, and cortex. Prazosine and clonidine tended to reduce HVA and DOPAC. The preferential alpha₂-antagonists, tolazoline and RX-781094A, had no measurable effects on DA metabolism even at high doses.Those compounds which in comparable doses increased DA metabolism inhibited³H-spiperone binding in the hippocampus. The effects in the striatum and cortex were smaller and did not show a relation to those in hippocampus or on DA metabolism. Only the yohimbine alkaloids antagonized amphetamine-induced stereotypies.The results suggest that the effects on DA metabolism at least of yohimbine, rauwolscine, and corynanthine are related to their intrinsic antidopaminergic properties. The same might be true, although with a lesser degree of certainty, for piperoxane, esproquin, and WB4101.Since many of the tested compounds possessing alpha-antagonistic properties interacted with the DA system, a close molecular relationship between alpha-noradrenergic and DA receptors might be anticipated. The preference of these compounds for the hippocampal subtype of DA receptors might indicate a particular role of the latter in the regulation of DA metabolism. On the other hand, the antagonism against haloperidol's enhancing effect on DA metabolism by clonidine suggests a modulatory NA influence on DA transmission. The observation that clonidine reduced the effects of yohimbine and piperoxane to a lesser degree than that of haloperidol, is in agreement with this notion.Part of this work has been presented at the 13th Meeting of the Union of Swiss Societies of Experimental Biology, Lausanne, March 26/27. 1981 (for abstract see Waldmeier and Bischoff, 1981).